CABOMETYX® approved by the European Commission

CABOMETYX® approved by the European Commission

On the 17th of May, 2018, Cabometyx® (cabozantinib) was approved by the European Commission for the first-line treatment of adult patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC).

Read more

Previous

Next